<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182932</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_HFM_101</org_study_id>
    <nct_id>NCT04182932</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of CJ-40010 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and immunogenicity of CJ-40010 after administration in
      healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enterovirus 71(EV71) and coxsackievirus A16(CVA16) are major causes of Hand-foot-and-mouth
      disease (HFMD) occurring in pediatric population. Although EV71 vaccine has been licensed in
      China, vaccine for CVA16-associated HFMD is currently not available anywhere. The purpose of
      this phase I study is to evaluate the safety and immunogenicity of EV71/CVA16 bivalent
      vaccine in healthy adults.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events of CJ-40010 (Safety of CJ-40010)</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>- Frequency and severity of adverse events up to 32 weeks post first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CJ-40010 : Anti-EV71 IgG titer</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Serum EV71-specific IgG titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CJ-40010 : Anti-CVA16 IgG titer</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Serum CVA16-specific IgG titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CJ-40010 : Geometric mean titer (GMT) of EV71 neutralizing antibody titers</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against EV71</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CJ-40010 : GMT of CVA16 neutralizing antibody titers</measure>
    <time_frame>Week 0 to Week 32</time_frame>
    <description>Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against CVA16</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hand, Foot and Mouth Disease</condition>
  <arm_group>
    <arm_group_label>CJ-40010 EV71 A dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-40010 EV71 B dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-40010 CVA16 C dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-40010 CVA16 D dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-40010 Bivalent E dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-40010 Bivalent F dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 EV71 vaccine A dose</intervention_name>
    <description>Inactivated vaccine against EV71, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 EV71 A dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 EV71 vaccine B dose</intervention_name>
    <description>Inactivated vaccine against EV71, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 EV71 B dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 CVA16 vaccine C dose</intervention_name>
    <description>Inactivated vaccine against CVA16, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 CVA16 C dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 CVA16 vaccine D dose</intervention_name>
    <description>Inactivated vaccine against CVA16, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 CVA16 D dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 Bivalent vaccine E dose</intervention_name>
    <description>Inactivated vaccine against EV71/CVA16, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 Bivalent E dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJ-40010 Bivalent vaccine high dose</intervention_name>
    <description>Inactivated vaccine against EV71/CVA16, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 Bivalent F dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, three doses, 28 days interval</description>
    <arm_group_label>CJ-40010 Bivalent E dose</arm_group_label>
    <arm_group_label>CJ-40010 Bivalent F dose</arm_group_label>
    <arm_group_label>CJ-40010 CVA16 C dose</arm_group_label>
    <arm_group_label>CJ-40010 CVA16 D dose</arm_group_label>
    <arm_group_label>CJ-40010 EV71 A dose</arm_group_label>
    <arm_group_label>CJ-40010 EV71 B dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women aged ≥19 to &lt;50 years at the time of screening tests

          -  Body mass index(BMI)* of ≥18.0 kg/m2 to ≤27.0 kg/m2, with body weight of ≥55.0 kg to
             ≤90.0 kg for men and ≥50.0 kg to ≤90.0 kg for women at the time of screening tests

             *BMI (kg/m2) = Body weight (kg) / {height (m)}2

          -  Determined by the investigator to be eligible for study participation based on the
             results of screening tests (medical examination by interview, physical examination,
             vital signs, ECG, and clinical laboratory tests) conducted within 4 weeks of the 1st
             IP administration

          -  Intact deltoid muscle* that allows administration of the investigational product

             *Those who have a wound, scar, tattoo, skin disorder or infection on the expected
             investigational product administration site (deltoid muscle) that can affect safety
             evaluation cannot enter the study

          -  Consent to use medically acceptable contraception* throughout the study

             *Medically acceptable contraception: Use of an intrauterine device with a demonstrated
             pregnancy failure rate, concurrent use of a barrier method (male or female) and
             spermicide, surgical contraception of the subject or partner (vasectomy,
             salpingectomy/tubal ligation, hysterectomy, bilateral oophorectomy)

          -  Negative finding from a pregnancy test (urine hCG) at the time of the screening visit,
             after using medically acceptable contraception prior to 30 days of screening for women
             of childbearing potential*

             *Women of childbearing potential: Women who have not passed 1 year after menopause or
             not surgically sterilized (hysterectomy, bilateral oophorectomy)

          -  Voluntary decision and provision of written consent on participation in this study

        Exclusion Criteria:

          -  History of a hand-foot-mouth disease or history of a disease related with
             enterovirus(EV) infection such as herpangina, viral meningitis, encephalitis, acute
             hemorrhagic conjunctivitis or myocarditis within 3 months prior to the 1st IP
             administration

          -  Medical history of an anaphylactic or similar acute reaction to CJ-40010 or similar
             vaccine

          -  Febrile disease or infectious disease within 2 weeks prior to the 1st IP
             administration

          -  Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP
             administration

          -  Vaccination with other prevention vaccine within 2 months prior to the 1st IP
             administration

          -  Use of an immunomodulator or immunosuppressant* within 3 months prior to the 1st IP
             administration

               -  e.g., Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus,
                  Sirolimus

               -  High dose corticosteroids (continuous use for 14 days or more at ≥20 mg/day for
                  Prednisolone. However, use of inhaled, intranasal or topical corticosteroids is
                  allowed irrespective of the administered dose).

          -  History of a Guillain Barre syndrome

          -  Excessive caffeine intake (&gt;5 units/day) or continuous alcohol consumption (&gt;21
             units/week, 1 unit = 10 g of pure alcohol) or incapable of abstention from alcohol
             during the study

          -  Participation in other clinical trial within 6 months prior to the 1st IP
             administration

          -  Pregnant or breastfeeding women

          -  Clinically significant hepatic, renal, neurological, respiratory, endocrine,
             hematology and oncology, cardiovascular, urological or psychiatric disease or such
             history

          -  Positive serological finding (type B hepatitis test, type C hepatitis test, human
             immunodeficiency virus(HIV) test)

          -  History of drug abuse or positive finding from a urine screening test for an abusive
             drug

          -  Use or of any prescription medication or oriental medicine within 2 weeks or any
             over-the-counter(OTC) medication, health functional food or vitamin within 1 week
             prior to the 1st IP administration (however, those who administered an allowed drug as
             specified in the other exclusion criterion can enter the study) or expected use of
             such products

          -  Administration of a blood product or blood-derived agent within 3 months prior to the
             1st IP administration

          -  Determined by the investigator to be ineligible for study participation due to other
             reason including clinical laboratory findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Young Wang</last_name>
    <phone>+82-2-6477-0286</phone>
    <email>sy.wang@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Yeon Nam</last_name>
    <phone>+82-2-6477-0277</phone>
    <email>jy.nam@kolmar.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>+82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
    <mesh_term>Mouth Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

